Literature DB >> 9250227

Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'.

P O Hansson1, L Welin, G Tibblin, H Eriksson.   

Abstract

BACKGROUND: Deep vein thrombosis (DVT) and pulmonary embolism (PE) are common public health problems. Still, little is known about the epidemiology and the natural history of venous thromboembolism.
METHODS: In the Study of Men Born in 1913, 855 men were followed up prospectively from the age of 50 years to the age of 80 years. Several cross-sectional samples, also of men born in 1913, were studied at the ages of 50, 54, 60, 67, 75, and 80 years. Objective methods were used to ascertain a diagnosis of DVT or PE, and all were confirmed by hospital records or autopsy reports. The follow-up rate in the longitudinal study was 98.2%.
RESULTS: In the longitudinal study, the incidence of DVT was 182 per 100,000 observation-years. Corresponding incidence rates were 98 for nonfatal PE, 107 for fatal PE, and 387 for all thromboembolic events. The cumulative probability for a venous thromboembolic event at different ages was estimated to be 0.5% by the age of 50 years and 10.7% by the age of 80 years. In the cross-sectional studies, a history of confirmed venous thromboembolism was found in 0.5% of the men at age 50 years, 0.9% at age 54 years, 1.3% at age 60 years, 2.0% at age 67 years, 4.5% at age 75 years, and 3.8% at age 80 years.
CONCLUSIONS: The results indicate a high incidence of DVT and PE in the general population. The incidence of thromboembolic events increases with age. The rate of fatal PE seems to be higher than estimated before, and PE constitutes almost 5% of all deaths during follow-up.

Entities:  

Mesh:

Year:  1997        PMID: 9250227

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  69 in total

Review 1.  Contrast-enhanced pulmonary MR imaging.

Authors:  O Haraldseth; T Amundsen; P A Rinck
Journal:  MAGMA       Date:  1999-08       Impact factor: 2.310

2.  Elevated plasma gas6 levels are associated with venous thromboembolic disease.

Authors:  Mark D Blostein; Isabelle Rajotte; Deepa P Rao; Christina A Holcroft; Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

3.  [Travel related thrombosis: media horror scenario or medical fact?].

Authors:  Wolfgang Schobersberger
Journal:  Wien Klin Wochenschr       Date:  2003-05-30       Impact factor: 1.704

4.  [Determining factors of a pulmonary embolism].

Authors:  Guacimara Ortega Sánchez; José Luis Torres Baile; María Teresa Lázaro Ayete
Journal:  Aten Primaria       Date:  2010-02-08       Impact factor: 1.137

5.  AKT2 regulates endothelial-mediated coagulation homeostasis and promotes intrathrombotic recanalization and thrombus resolution in a mouse model of venous thrombosis.

Authors:  Wanmu Xie; Lin Zhang; Wei Luo; Zhenguo Zhai; Chen Wang; Ying H Shen
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

6.  Incidence of venous thromboembolic events among nursing home residents.

Authors:  Josephine P Gomes; Wassim H Shaheen; Son V Truong; Edward F Brown; Brent W Beasley; Byron J Gajewski
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

Review 7.  Thromboembolic disease in vasculitis.

Authors:  Gunnar Tomasson; Paul A Monach; Peter A Merkel
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

Review 8.  Treatment of deep vein thrombosis: what factors determine appropriate treatment?

Authors:  James D Douketis
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

9.  [Vena cava filter. Which indications remain in the era of differentiated anticoagulation?].

Authors:  A H Mahnken
Journal:  Radiologe       Date:  2013-03       Impact factor: 0.635

10.  Socioeconomic factors and concomitant diseases are related to the risk for venous thromboembolism during long time follow-up.

Authors:  Nazim Isma; Juan Merlo; Henrik Ohlsson; Peter J Svensson; Bengt Lindblad; Anders Gottsäter
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.